# Q3 REPORT

#### JOACIM LINDOFF, CEO & REINHARD MAYER, CFO OCTOBER 18, 2016



# OVERVIEW GENERAL BUSINESS

JOACIM LINDOFF, CEO

## **Q3 IN BRIEF**

#### A QUARTER WITH KEY STRATEGIC DECISIONS


- **Organic top line growth:** Negative order intake and flat net sales
- **Gross Margin:** Margin up 0.5 pp due to currency effects and positive product mix
- EBITA-growth\*: +16.3% to SEK 963 M (828)
- **Restructuring costs:** Increased to SEK 732 M (213)
  - Due to FDA provision, write-down of capitalized development project and costs due to change of management
- FDA Update:
  - SEK 400 M in additional provision related to the ongoing remediation process mainly in Hechingen
- Decision after Q3:
  - Strategic review to ensure profitable growth in all three BCU's
  - Preparation of distribution of Patient & Post-Acute Care (former Extended Care) to shareholders
  - A split would increase the ability for both companies to execute their strategies and to enhance shareholder value


## **TOP LINE DEVELOPMENT**

#### CHALLENGING ORDER INTAKE DURING THE QUARTER

- Organic order intake –3.2%
  - Negative organic order growth in all BCU's
  - Stable growth in EMEA while negative development in both APAC and Americas
- Organic Net sales +0.2 %
  - Growth in ACT while declining net sales in SW and PPAC
  - APAC developed in line with LY while Americas is growing and EMEA shows small decline in the quarter

## **GETINGE GROUP**





## **BCU UPDATE – SURGICAL WORKFLOWS**

#### LOWER SALES COMPENSATED BY CONTINUED COST REDUCTIONS

- Weak order intake development
  - Organic order growth down by 1.1% in the quarter with positive growth in EMEA
- Negative growth in net sales
  - Organic decrease of 0.1 %. Strong growth in both Life Science and Integrated Workflow Solutions but Surgical Workplaces shows negative impact
- Gross profit
  - Gross margin up 1.2 pp
- EBITA\*
  - Selling and admin expenses down in the quarter improving the EBITA margin with 2.8 pp

	Q3 2016	Q3 2015		YTD 2016	YTD 2015	
Segment Overview, mSEK	Surgical Wo	orkflows	%	Surgical W	orkflows	%
Order Intake, external	2 710	2 733	-0,8%	7 656	7 846	-2,4%
Net Sales, external	2 375	2 389	-0,6%	6 702	6 909	-3,0%
Cost of Goods/Services sold	-1 425	-1 461	2,5%	-4 184	-4 312	3,0%
Gross Profit	950	928	2,4%	2 518	2 597	-3,0%
Gross margin, %	40,0%	38,8%	1,2%	37,6%	37,6%	0,0%
EBITA before restructuring-,						
integration and acquisition costs	293	228	28,5%	531	418	27,0%
EBITA margin, %	12,3%	9,5%	2,8%	7,9%	6,1%	1,8%
Restructuring-, integration and						
acquisition costs	- 49	- 18	-172,2%	- 129	- 91	-41,8%
EBIT	237	202	17,3%	382	305	25,2%
EBIT margin, %	10,0%	8,5%	1,5%	5,7%	4,4%	1,3%

Surgical workflows	2 710	2 733	-1.1%	7 656	7 846	-0.7%
APAC	635	633	-4.4%	1 657	1 641	0.7%
Americas	652	736	-12.7%	2 026	2 166	-5.2%
EMEA	1 423	1 364	6.6%	3 973	4 039	1.2%
Order Intake, external	2016	2015	%*	2016	2015	%*
	Q3	Q3		YTD	YTD	

\* AC adjusted for currency, acquisitions and divestments

\* Before restructuring, acquisition and integration costs

#### **BCU UPDATE – ACUTE CARE THERAPIES** BETTER MARGINS DUE TO GOOD COST CONTROL

#### • Order intake decrease

- Organic growth of -4.1% with decline in all markets, mainly due to decrease in Critical Care and Cardiopulmonary
- Growth in net sales
  - Organic growth of 1.3% due to positive growth in both Americas and EMEA, while APAC declines due to Australia
- EBITA\*
  - + 13.4 % due to higher gross margin and lower S&A spending
- Restructuring, integration and acquisition costs
  - Restructuring costs including FDA and write-down of capitalized development project

\* Before restructuring, acquisition and integration costs

	Q3 2016	Q3 2015			YTD 2016	ΥT	D 2015	
Segment Overview, mSEK	Acute Care 1	Therapies	%	6	Acute Car	e Therapi	es	%
Order Intake, external	2 728	2 816	-3,	,1%	8 567	8	3 482	1,0%
Net Sales, external	2 748	2 695	2,	0%	8 155	8	3 175	-0,2%
Cost of Goods/Services sold	-1 188	-1 178	-0,	8%	-3 593	-	3 643	1,4%
Gross Profit	1 560	1 517	2,	8%	4 562	4	532	0,7%
Gross margin, %	56,8%	56,3%	0,	5%	55,9%	55	5,4%	0,5%
EBITA before restructuring-,								
integration and acquisition costs	541	477	13	,4%	1 403		1 451	-3,3%
EBITA margin, %	19,7%	17,7%	2,	0%	17,2%	1	7,7%	-0,5%
Restructuring-, integration and								
acquisition costs	- 594	- 141	-32	1,3%	- 694	-	253	-174,3%
EBIT	- 192	185	-203,	,8%	296		751	-60,6%
EBIT margin, %	-7,0%	6,9%	-13	3,9%	3,6%	g	,2%	-5,6%
			Q3	Q3		YTD	YTD	
	Order Intake, ex	ternal	2016	2015	%*	2016	2015	%*
	EMEA		822	862	-3.4%	2 645	2 651	2.3%
	Americas		1 431	1 444	-2.0%	4 465	4 410	2.0%
	APAC		475	510	-11.2%	1 457	1 421	2.6%
	Acute Care The	rapies	2 728	2 816	-4.1%	8 567	8 482	2.2%

\* AC adjusted for currency, acquisitions and divestments

#### GETINGE GROUP **BCU UPDATE – PATIENT & POST-ACUTE CARE** UNFAVORABLE PRODUCT MIX DECREASING THE GP MARGIN

#### Order intake down 4,9% (org)

- Negative growth in Americas and APAC mainly due to lower demand in the capital segment
- Rental and Service down due to large orders last year
- Net sales decrease 0,9% organically
  - Strong quarter for Patient Handling but • lower sales in Rental and Service offsetting the net sales drop
- Gross profit ۲
  - Gross margin down 0.8 pp
- EBITA\* •

۰

· Good cost control in the quarter increases EBITA\* with 8.1 % despite lower GP

	Q3 2016	Q3 2015			YTD 2016	5 YT	D 2015	
Segment Overview, mSEK	Patient & Pos	st-Acute	Q	6	Patient &	Post-Acu	te	%
Order Intake, external	1 738	1 848	-6	,0%	5 337	-	5 777	-7,6%
Net Sales, external	1 806	1 841	-1	,9%	5 376		5 734	-6,2%
Cost of Goods/Services sold	-1 041	-1 045	0,	4%	-3 003		-3 149	4,6%
Gross Profit	765	796	-3	,9%	2 373	2	585	-8,2%
Gross margin, %	42,4%	43,2%	-0	,8%	44,1%	4	15,1%	-1,0%
EBITA before restructuring-, integration and acquisition costs	187	173	8	.1%	596		541	10,2%
EBITA margin, %	10,4%	9,4%		,0%	11,1%	:	9,4%	1,7%
Restructuring-, integration and acquisition costs	- 5	- 46	89	0,1%	- 53		- 150	64,7%
EBIT	152	94	61,	7%	453		291	55,7%
EBIT margin, %	8,4%	5,1%	3,	3%	8,4%		5,1%	3,3%
	Order Intake, exte	ernal	Q3 2016	Q3 2015	%*	YTD 2016	YTD 2015	%*
	EMEA		858	893	-1.4%	2 654	2 792	-1.9%
	Americas APAC		690 190	733	-5.4%	2 086 597	2 248 737	-5.2% -16.4%
	Patient & Post-A		1 738	1 848	-17.4%	5 3 3 7	5 777	-16.4%

VTD 0040

VTD OOAT

\* AC adjusted for currency, acquisitions and divestments

<sup>\*</sup> Before restructuring, acquisition and integration costs

## **FDA & REMEDIATION UPDATE**

IMPROVEMENT WORK AT HECHINGEN CONTINUED AT THE SAME ROBUST RATE

- Intense work has been carried out on activities under the improvement plan during the quarter
- An ongoing dialogue with the FDA still awaiting response on the plan for Hechingen
- Getinge has reserved an additional SEK 400 M to for the remediation program, mainly related to Hechingen

# FDA & REMEDIATION BACKGROUND GETINGE GROUP

#### 4 LEGAL ENTITIES IN PHASE 1 OF 3 - HARD TO ESTIMATE TOTAL COST

- 4 legal entities covered by the Consent Decree
- The Consent Decree consists of 3 phases
- All Getinge Group sites are in phase 1
- Annual inspections
  - The Consent Decree we reached with the FDA at the start of 2015 entails compulsory annual inspections at the production units encompassed by the Decree
  - These inspections will determine whether additional investments are needed to meet the FDA's requirements and expectations
- Accordingly, we cannot rule out additional sanctions or costs

## **FOCUSED STRATEGY**

BUILD ON SOURCES OF STRENGTHS

- Strategic review clarifying long-term strategy for the company
- Build on core competences to drive sustainable and profitable growth
- Focus needed
  - Surgical Workflows
  - Acute Care Therapies

• Patient & Post-Acute Care

## FOCUS ON ACT AND SW

TWO AREAS OF FOCUS

	<b>Acute Care Therapies</b> Cardiovascular and Respiratory	2 Surgical Workflows Hospital Infrastructure and Services
Value proposition	Improve outcome via cardiovascular and respiratory therapies to offer superior therapies in selected areas with growing unmet need	Offer integrated solutions to meet customer needs in capital, services, consultative knowledge, and IT
Fundamentals	<ul> <li>Attractive long term growth prospects</li> <li>Building on existing Getinge leadership and relationships in specific categories</li> </ul>	<ul> <li>Increased demand in order to enhance quality, safety and productivity</li> <li>Need for integrated solutions in areas where Getinge has strong presence</li> </ul>

## FOCUS ON PPAC


#### BUILD ON SOURCES OF STRENGTHS - AS A LISTED COMPANY

	3	•	B
	Patient & Post-Acute Care Integrated and effective solutions for mobility		as ta
Value proposition	Deliver integrated solutions to improve the lives of people affected by reduced mobility and enable caregivers to provide better and more productive health care	_	
Fundamentals	<ul> <li>Large adressable market with recurring revenue and with favourable drivers (aging population, increased incidence of chronic diseases)</li> </ul>	٠	TI CC
	<ul> <li>Comprehensive care offering and category leadership across Acute and Long Term Care settings</li> </ul>		
	<ul> <li>Global footprint, well established customer relationships and large installed base</li> </ul>		
	<ul> <li>Focused approach to managing business unleashes true potential and drives sustainable profitable growth</li> </ul>		

- Based on a corporate wide strategic
   assessment, the Board of Directors has
   tasked the management of Getinge Group to:
  - Prepare a distribution of Patient & Post-Acute Care to Getinge's shareholders
  - Presentation to EGM in fall 2017
  - Listing in Q1 2018, at the latest
- The potential spin off, would enable both companies to:
  - Have a distinct focus on areas of strength
  - Enhance ability to leverage market
     opportunities
  - Maximize customer centricity and increase shareholder value

## **PATIENT & POST-ACUTE CARE**

PRODUCT PORTFOLIO - STRONG GLOBAL MARKET POSITIONS



## **TRANSFORMATION PROGRAM**

#### CONTINUES BUT EXPECTED TO BE AFFECTED BY THE SPLIT

- BIG 5 cost efficiency program
  - Continued good cost control
  - Savings amounted to SEK 95-100 M in Q3
  - Accumulated savings YTD amounts to SEK 255-270 M

#### • Effects from the distribution of Patient & Post-Acute Care

- The current One Getinge transformation program continues with Acute Care Therapies and Surgical Workflows
- Further integration initiatives related to PPAC will be paused to ensure that we build a sustainable standalone business

# OVERVIEW FINANCIALS

REINHARD MAYER, CFO

# **Results**

## PERFORMANCE

#### CONTINUED COST REDUCTIONS

#### • Order intake

- Stable growth in EMEA but decline in both Americas and APAC
- All BCU:s down in the quarter
- Net sales growth 0.1% (org. 0.2%)

#### Gross Profit

- Higher GP due to positive currency transaction effects and the reduction of medical device tax
- Good cost control in Supply Chain

#### • S&A

- Big 5 on plan with selling and admin expenses reduced by 2.1 %
- EBITA\* development
  - EBITA\*-growth 16.3% increasing the margin to 13.9%

SEK M	Q3 2016	Q3 2015	Change %	YTD 2016	YTD 2015	Change %
Order intake, SEK M	7 176	7 397	-3,0%	21 560	22 105	-2,5%
Organic			-3,2%			-0,7%
FX-effects			0,0 pp			1,7 pp
Acquisitions / divestments			-0,2 pp			0,1 pp
Net Sales	6 929	6 925	0,1%	20 233	20 818	-2,8%
Organic			0,2%			-1,1%
FX-effects			0,4 pp			1,7 pp
Acquisitions / divestments			-0,3 pp			0,0 pp
Gross Margin, %	47,3	46,8	0,5	46,7	46,7	0,0
Selling expenses (in % of net sales)	22,2	23,4	-1,2	22,9	23,9	-1,0
Admin expenses (in % of net sales)	12,1	11,6	0,5	12,3	12,2	0,1
EBITA*, SEK M	963	828	16,3%	2 371	2 260	4,9%
EBITA* margin, %	13,9	12,0	1,9	11,7	10,9	0,8

	Q3	Q3		YTD	YTD	
Order Intake, external	2016	2015	%*	2016	2015	%*
EMEA	3 103	3 119	1,6%	9 272	9 482	0,6%
Americas	2 773	2 913	-5,5%	8 577	8 824	-1,6%
APAC	1 300	1 365	-9,0%	3 711	3 799	-1,9%
Group Total	7 176	7 397	-3,2%	21 560	22 105	-0,7%

\* AC adjusted for currency, acquisitions and divestments

## **RESTRUCTURING COST**

SIGNIFICANT INCREASE IN RESTRUCTURING COST DUE TO THREE FACTORS

1.	FDA provision	SEK 400 M
2.	Write-down of capitalized development project	SEK 158 M
3.	Cost for changes among senior executives	<b>SEK 70 M</b>
•	Earlier FY guidance on Restructuring cost	SEK 800 M
•	New FY guidance on Restructuring cost	SEK 1 260 M

### **FX EFFECTS** POSITIVE EXCHANGE RATE EFFECTS IN Q3

#### Positive effects in the quarter

 Exchange-rate effects had a positive impact of SEK 32 M on EBITA\* in the quarter, of which transaction effects accounted for SEK 61 M and translation effects for SEK -29 M

#### Positive full year effects

 Currency transaction effects are expected to have a positive impact of approximately SEK 150 M (273) on the Group's 2016 earnings

	Transaction	Translation	
MSEK	effect	effect	Total
Gross Profit	61	- 50	11
EBITA*	61	- 29	32
EBIT	61	- 26	35

# **Balance Sheet**

## **BALANCE SHEET**

#### FOCUS ON NET DEBT DEVELOPMENT

- Net debt development
  - Adjusted change in net debt for the period amounting to SEK -697 M
- Net debt to equity ratio
  - Decreased 3.8 pp to 121.0%
- Net debt to EBITDA before restructuring
  - Decrease from 4.0 to 3.9 for the period

Assets,	2016	2015	2015
MSEK	30-Sep	30-Sep	31-Dec
Intangible assets	30 697	30 832	30 543
Tangible fixed assets	4 691	4 846	4 699
Financial fixed assets	1 695	1 552	1 374
Inventory	6 139	6 182	5 409
Accounts receivable	6 373	5 858	7 470
Other current receivables	2 843	2 742	2 272
Cash and cash equivalents	1 812	1 544	1 46
Total assets	54 250	53 556	53 235
Shareholders' equity & Liabilities	, 2016	2015	2015
MSEK	30-Sep	30-Sep	31-Dec
Shareholders' equity	19 251	18 855	19 593
Pension Provision	3 176	3 171	3 052
Other interest bearing liabilities	21 929	21 898	21 283
Other Provisions	2 382	2 402	2 243
Accounts Payable	1 753	1 935	1 98
Other non interets-bearing liabilities	5 759	5 295	5 078
Total Equity & Liabilities	54 250	53 556	53 235

Change in net debt,	2016	2015	2015
mSEK	30-Sep	30-Sep	31-Dec
Change in net debt	425	983	326
Currency effect	- 726	- 848	- 581
Acquisitions/Divestments	- 214	297	261
Actuarial gains/losses pensions, gross	- 182	89	- 23
Adjusted change in net debt	- 697	521	- 17
Net debt to equity ratio	121.0%	124.8%	116.7%
Net debt to EBITDA before restructuring	3.90	4.00	3.89

# **Cash Flow**

## **CASH FLOW**

#### CASH FROM OPERATIONS IMPACTED BY TAX AND WORKING CAPITAL REDUCTIONS

- Operating cash flow at SEK 725 M representing a increase by SEK 1 M in Q3 compared to last year
- Cash Conversion at 89.5 % compared to 69.0 % last year
- Investing activities decreased by SEK 2 M relative to last year, in total amounting to SEK 376 M
- Cash flow after net investments SEK 349 M, increased by SEK 3 M compared to last year

Q3	Q3	YTD	YTD	FY
2016	2015	2016	2015	2015
810	1 046	2 773	3 019	5 187
352	-22	211	-199	-261
29	27	61	42	230
-159	-184	-480	-558	-732
-139	-124	-401	-650	-858
893	743	2 164	1 654	3 566
-168	-19	-276	320	-108
725	724	1 888	1 974	3 458
89,5%	69,0%	68,1%	65,4%	66,7%
-376	-378	-1 351	-937	-1 793
349	346	537	1 037	1 665
-646	352	-449	385	-422
-297	698	88	1 422	1 243
	2016 810 352 29 -159 -139 893 -168 725 89,5% -376 349 -646	2016         2015           810         1 046           352         -22           29         27           -159         -184           -139         -124           893         743           -168         -19           725         724           89,5%         69,0%           -376         -378           349         346           -646         352	2016         2015         2016           810         1 046         2 773           352         -22         211           29         27         61           -159         -184         -480           -139         -124         -401           893         743         2 164           -168         -19         -276           725         724         1 888           89,5%         69.0%         68.1%           -376         -378         -1 351           349         346         537           -646         352         -449	2016         2015         2016         2015           810         1 046         2 773         3 019           352         -22         211         -199           29         27         61         42           -159         -184         -480         -558           -139         -124         -401         -650           893         743         2 164         1 654           -168         -19         -276         320           725         724         1 888         1 974           89,5%         69,0%         68,1%         65,4%           -376         -378         -1 351         -937           349         346         537         1 037           -646         352         -449         385

# OUTLOOK

JOACIM LINDOFF, CEO

# OUTLOOK

- We expect moderately negative growth in organic net sales in 2016
- **Currency transaction effects** are expected to have positive impact of approximately SEK150 M for 2016
- **Restructuring costs for the full-year 2016** are expected to amount to approximately SEK 1 260 M (657)
- The financial consequences of the Consent Decree with the FDA, excluding costs for the remediation program, are expected to have a negative impact of approximately SEK 130 M on the Group's 2016 operating profit

# SUMMARY

# Q&A

# **THANK YOU**

# **FORWARD LOOKING INFORMATION** GETINGE GROUP

This document contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.